NEWM&A

Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy

Published on 4/19/2026

#ZLAB#AMGN#oncology#biopharmaceuticals#cancer
Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy

AI Summary

Zai Lab (ZLAB) and Amgen (AMGN) have announced a partnership to evaluate a combination therapy for lung cancer. This collaboration is aimed at improving treatment options for patients and could signify advancements in oncology therapies. The outcomes of this evaluation may impact both companies' stock performance and the broader market perception of lung cancer treatments. Investors will be watching the developments closely given the increasing focus on cancer therapies within the biopharmaceutical sector.

Source: Read original article (opens in new tab)

Related News

QXO to Acquire TopBuild for $17 Billion in Major Deal
M&A

QXO to Acquire TopBuild for $17 Billion in Major Deal

Apr 19

QXO Acquires TopBuild for $17 Billion Investment
M&A

QXO Acquires TopBuild for $17 Billion Investment

Apr 19

Sigma Lithium (SGML) Secures $100M Bank Guarantee for Expansion
M&A

Sigma Lithium (SGML) Secures $100M Bank Guarantee for Expansion

Apr 19

United Airlines (UAL) Flight Diverted to Pittsburgh Over Security Concern
M&A

United Airlines (UAL) Flight Diverted to Pittsburgh Over Security Concern

Apr 19